Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03514407
Recruitment Status : Terminated (Strategic Business Decision)
First Posted : May 2, 2018
Last Update Posted : July 16, 2020
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.

Condition or disease Intervention/treatment Phase
Relapsed Ewing Sarcoma Drug: INCB059872 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Actual Study Start Date : June 27, 2018
Actual Primary Completion Date : June 25, 2020
Actual Study Completion Date : June 25, 2020


Arm Intervention/treatment
Experimental: INCB059872
INCB059872
Drug: INCB059872
Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.




Primary Outcome Measures :
  1. Number of adverse events [ Time Frame: Screening through 30 days after last dose of study treatment, up to approximately 6 months. ]
    Defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of a drug in humans, whether or not considered drug-related.


Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: Up to approximately 6 months. ]
    Defined as the percentage of participants who have a complete response or partial response as determined by investigator assessment of response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

  2. Cmax of INCB059872 [ Time Frame: Up to approximately 2 weeks. ]
    Defined as maximum observed plasma concentration.

  3. tmax of INCB059872 [ Time Frame: Up to approximately 2 weeks. ]
    Defined as time to maximum concentration.

  4. t½ of INCB059872 [ Time Frame: Up to approximately 2 weeks. ]
    Defined as apparent terminal-phase disposition half-life.

  5. Cl/F of INCB059872 [ Time Frame: Up to approximately 2 weeks. ]
    Defined as apparent oral dose clearance.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies.
  • Must not be a candidate for potentially curative therapy or standard-of-care approved therapy.
  • Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology.
  • Eastern Cooperative Oncology Group performance status 0 to 2.
  • Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

  • Receipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug.
  • Must have recovered (≤ Grade 2 or at pretreatment baseline) from adverse events (AEs) from previously administered therapies except for stable chronic toxicities (≤ Grade 2) not expected to resolve.
  • Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed.
  • Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval.
  • Laboratory values outside the protocol-defined range at screening.
  • History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03514407


Locations
Layout table for location information
United States, California
UCLA Jonsson Comprehensive Cancer
Los Angeles, California, United States, 90095
United States, Florida
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida, United States, 32224
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, Tennessee
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Italy
Istituto Ortopedico Rizzoli
Bologna, Italy, 40136
Policlinico Sant'orsola-Malpighi
Bologna, Italy, 40138
Ospedale Pediatrico Bambino Gesu IRCCS
Rome, Italy, 00146
Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain, 08035
Hospital Clínico San Carlos
Madrid, Spain, 28040
United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Sponsors and Collaborators
Incyte Corporation
Investigators
Layout table for investigator information
Study Director: Fred Zheng, MD Incyte Corporation
Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT03514407    
Other Study ID Numbers: INCB 59872-103
First Posted: May 2, 2018    Key Record Dates
Last Update Posted: July 16, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
Relapsed Ewing sarcoma
bromodomain-containing protein (BRD) inhibitor
lysine demethylase 1 (LSD1) inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue